-
IFM Due signs immunotherapy deal with Novartis
pharmaceutical-technology
September 10, 2019
IFM Due, a subsidiary of IFM Therapeutics, has entered a collaboration and exclusive option agreement with Novartis...
-
Cidara and Mundipharma sign rezafungin drug development deal
pharmaceutical-technology
September 05, 2019
US-based biotech Cidara Therapeutics has partnered with UK-based Mundipharma in a deal valued at more than $568m to develop and commercialise its anti-fungal drug rezafungin.
-
Sofinnova sells Breath Therapeutics to Zambon in $550m deal
pharmaceutical-technology
July 29, 2019
Venture capital firm Sofinnova Partners has dispossessed its portfolio company Breath Therapeutics to Italian pharmaceutical firm Zambon for a total consideration of up to $550m (€500m), including a €140m upfront payment.
-
Merck buys Tilos Therapeutics in a $773M deal
biospectrumasia
June 13, 2019
Merck Gains Portfolio of Investigational Antibodies Modulating TGFβ
-
AstraZeneca signs major cancer drug deal
bbc
April 18, 2019
British pharmaceutical giant AstraZeneca has signed a deal with Japanese firm Daiichi Sankyo to help develop and sell the cancer drug trastuzumab deruxtecan.
-
AstraZeneca and Daiichi Sankyo sign $6.9bn cancer drug development deal
pharmaceutical-technology
April 11, 2019
AstraZeneca has entered a deal worth up to $6.9bn with Daiichi Sankyo to develop and commercialise cancer drug trastuzumab deruxtecan...
-
As Amgen seeks to can Aimovig collaboration, Novartis sues to save the deal
fiercepharma
April 08, 2019
Novartis and Amgen were the first to tap into a hot market with their CGRP migraine prevention drug Aimovig……
-
Sanofi to pay Regeneron $462 million in revised immuno-oncology deal
expressbpd
January 09, 2019
The two companies said the new arrangement would give Sanofi increased flexibility to advance its early-stage immuno-oncology pipeline, while Regeneron retains all rights to its other immuno-oncology discovery and development programmes
-
Bristol-Myers Squibb to buy Celgene
pharmatimes
January 08, 2019
Bristol-Myers Squibb has announced that it is to acquire Celgene, in order to “create a premier innovative biopharma company” and expand its cancer and immunotherapy offering.
-
Boehringer Ingelheim chops 295 jobs in France but vows $380M in animal health investments
fiercepharma
December 12, 2018
When German pharma Boehringer Ingelheim completed a $12.5 billion asset swap with France’s Sanofi in 2016, BI traded its consumer health business for Sanofi’s veterinary unit and agreed